Tag Archives | cystic fibrosis

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

http://mo-pie.com/?page_name=index-96 Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates

order neurontin overnight Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]

Continue Reading 0

Large Cap Biopharma Performance Update 2018-Part 1

buy generic Lyrica online Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have outperformed the market. Here are some metrics on […]

Continue Reading 0

ACA: Uncertainty Remains After Healthcare Bill Failure But Stocks Get a Second Wind…Update-1

Update-1… JY 19…Biotech and Healthcare Stocks Continue to Rally IBB breaks through top to $322.92 up 21.68% YTD; XBI up 1.34% today 35.4% YTD; XLV up 17.6% YTD. Rayno Life Science top winners YTD: ABBV up 18.19%, AMGN up 22.6%, BLUE up 55% YTD, FMI up 114.7%, RHHBY up 12.86%. All beating the S&P. BMY […]

Continue Reading 0

Large Cap Biopharmaceutical Valuations: Q1 2017

May 8, 2017  Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%.  The large cap focused IBB […]

Continue Reading 0

Vertex (VRTX) Soars on Clinical Data and Boosts Biotech Stocks…Updates

Update…3/31/17 Performance %: March and YTD FBT  -0.83, +15.87 FBIOX  -2.43, +15.79  * Fidelity ahead of IBB in 2017 IBB   -3.05,+10.5 QQQ +1.04, +11.73 XBI   -2.82, +17.15 XLV   -1.9, +7.86 Notable Rayno Portfolio Picks %: March and YTD ABBV  +2.9,  +4.08 AMGN  -8.95, +12.22 BLUE  +7,  +47.33 FMI +13.85  +82.2 HOLX  +3.18, […]

Continue Reading 0

Biotechs Get a Turbo Boost from Biogen(BIIB)…Update-1 GILD

Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by $1B to the $29,5B-$31.5B range. Pricing pressures continued on Hep-C drugs and new […]

Continue Reading 0

Biotech Winners 2015: Rayno Mid Caps Were Up 29.6%

Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015  and the Mid-Caps also beat despite a big loss by Clovis Oncology after the FDA required more data on its lung cancer drug. The […]

Continue Reading 0

Biotech Stocks Eke Out a Rally: Regeneron (REGN) Soars…Update-1 Caution

August 6…Rally Fails: Sell-Off Underway 11:24A EDT The sell-off in biotech began at the opening and continues two hours later. The speculative smaller cap Exchange Traded Fund XBI is down 3%. There is a red screen across the board with many high fliers down 4%. The IBB is down 2.5%. 1:45 P EDT Go back to […]

Continue Reading 0

Rayno Life Science Stocks Move Higher: CLVS, RHHBY-ASCO Preview

Rayno Biopharmaceutical Stocks– ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a valuation of only $3.4B and three platform products in the pipeline including companion […]

Continue Reading 0